Chromomycosis, an unusual cause of cicatricial ectropion: a case report

Rios, José Eduardo Simarro; Paiva, Carolina Bonfim de; Paula, Gabriela Moura de; Figueiredo, Wanderley Ribeiro Borges; Arantes, Julio César Daher; Almeida, Fábio Marques de; Limongi, Roberto Murilo

doi:10.5935/0004-2749.20170012

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…O primeiro grupo formado por ITZ, TBF, RVC, PCZ e VCZ identificou-se os antifúngicos mais ativos (7,8,13,15,16) . No segundo grupo constituído por ANF, 5-FLU, ANI, ISA, FCZ e CTZ identificou-se os antifúngicos menos ativos (6,24,25,26) . Fonte: Os autores, 2021.…”

Section: Métodosunclassified

Descrição Da Farmacoterapia Da Cromoblastomicose: Revisão Da Literatura

Costa¹,

Monteiro²,

Moura³

et al. 2022

RACF

View full text Add to dashboard Cite

Introdução: A cromoblastomicose (CBM) é uma micose por implantação fúngica na pele, de evolução crônica, causada pela inoculação traumática de fungos dematiáceos. Objetivos: identificar a partir de uma análise na literatura os antifúngicos e as associações terapêuticas mais utilizados no tratamento, assim como, determinar as doses eficazes. Métodos: a pesquisa foi realizada a partir de uma revisão integrativa, com busca eletrônica de artigos nas bases de dados SCIELO, PUBMED, BVS e CINHHL através de descritores, "farmacoterapia da CBM", "doses e associações terapêuticas" no período de 2011 a 2021. Resultados e discussão: os principais antifúngicos utilizados no tratamento da CBM foram: Itraconazol (ITZ) em doses terapêuticas de 200 a 400 mg/dia, Terbinafina (TBF) de 150 a 1000 mg/dia e Posaconazol (PCZ) 400 a 800 mg/dia. Nas combinações antifúngicas, observou-se que ITZ + TBF foi a mais sugerida entre os artigos avaliados. Os dados mostraram que o ITZ e TBF foram utilizados por um período de 6 a 12 meses com boa resposta clínica. O PCZ pode ser uma opção de tratamento nas formas graves e refratárias, apesar de seu uso nesta patologia ainda se encontra limitado devido ao seu alto custo. Conclusão: CBM é uma micose negligenciada e difícil tratar, especialmente nas formas clínicas mais graves. O ITZ entre os antifúngicos estudados é o mais eficaz tanto em teste de suscebilidade in vitro como em situações clínicas. A interação medicamentosa entre ITZ+TBF é a mais eficiente entre os artigos avaliados na literatura, tornando uma alternativa terapêutica.

show abstract

Section: Métodosunclassified

Descrição Da Farmacoterapia Da Cromoblastomicose: Revisão Da Literatura

Costa¹,

Monteiro²,

Moura³

et al. 2022

RACF

View full text Add to dashboard Cite

show abstract

“…However, there are reports of epidemiological and microbiological research that certify the presence of this disease in nearly the entire country, 7,[12][13][14][15][16][17][18][19][20][21] with an estimated prevalence of 0.098 cases per 1,000,000 inhabitants. 11 In the scientific literature, there are few case reports of chromoblastomycosis from the state of Mato Grosso, in central-western Brazil.…”

Section: Introductionmentioning

confidence: 99%

“…10 , 11 In Brazil, the actual disease incidence and prevalence are largely unknown, as it is not mandatory to notify this disease. However, there are reports of epidemiological and microbiological research that certify the presence of this disease in nearly the entire country, 7 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 with an estimated prevalence of 0.098 cases per 1,000,000 inhabitants. 11 …”

Section: Introductionmentioning

confidence: 99%

Molecular epidemiology and clinical‐laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil

Guevara

Nery

Melhem

et al. 2022

Mycoses

View full text Add to dashboard Cite

Introduction Chromoblastomycosis is a disease caused by melanized fungi, primarily belonging to the genera Fonsecaea and Cladophialophora, mainly affecting individuals who are occupationally exposed to soil and plant products. This research aimed to determine the clinical, epidemiological and laboratory characteristics of chromoblastomycosis in the state of Mato Grosso, Brazil. Materials and Methods Patients diagnosed with chromoblastomycosis treated at the Júlio Müller University Hospital, Cuiabá, Brazil, from January 2015 to December 2020, whose isolates were preserved in the Research Laboratory of the Faculty of Medicine of the Federal University of Mato Grosso. Isolates were identified by partly sequencing the Internal Transcribed Spacer (ITS) and β‐tubulin (BT2) loci. AFLP fingerprinting was used to explore the genetic diversity. Susceptibility to itraconazole, voriconazole, 5‐fluorocytosine, terbinafine and amphotericin B was determined by the broth microdilution technique. Results Ten patients were included, nine were male (mean age = 64.1 years). Mean disease duration was 8.6 years. Lesions were mainly observed in the lower limbs. Predominant clinical forms were verrucous and scarring. Systemic arterial hypertension and type II diabetes mellitus were the predominant comorbidities. Leprosy was the main concomitant infectious disease. Fonsecaea pedrosoi was the unique aetiological agent identified with moderate genetic diversity (H = 0.3934–0.4527; PIC = 0.3160–0.3502). Antifungal agents with the highest activity were terbinafine, voriconazole and itraconazole. Conclusion Chromoblastomycosis is affecting the poor population in rural and urban areas, mainly related to agricultural activities, with F. pedrosoi being the dominant aetiologic agent. All isolates had low MICs for itraconazole, voriconazole and terbinafine, confirming their importance as therapeutic alternatives for chromoblastomycosis.

show abstract

Chromoblastomycosis in Latin America and the Caribbean: Epidemiology over the past 50 years

et al. 2021

View full text Add to dashboard Cite

Chromoblastomycosis is a chronic disease caused by melanized fungi that mainly affect individuals performing soil-related labour. The objective of this study was to analyse the epidemiological and clinical characteristics of chromoblastomycosis in Latin America and the Caribbean by an extensive literature review. An integrative review was performed of English, French, Portuguese, and Spanish publications in LILACS, SciELO, PubMed, SCOPUS and Web of Science databases covering the period 1969–2019. A total of 1,211 articles were identified, of which 132 were included in the review, covering 2,081 patients, 80.3% were male, the mean age was 56.1 years. The mean duration of the disease was 10.8 years. The lesions were mainly described in the lower limbs (60%). The most frequent clinical forms were verrucous (46.4%) and tumorous (21.7%). Major disease symptoms and signs consisted of itching and pain. Bacterial infection and functional limitation were important complications. Immunosuppression post-kidney transplantation was the most frequent comorbidity while leprosy was the main concomitant infectious disease. Fonsecaea pedrosoi and Cladophialophora carrionii were the predominant etiological agents. Majority of the cured cases were treated with itraconazole as monotherapy or in combination with other antifungals, surgery or cryosurgery. Chromoblastomycosis affects hundreds of rural workers in Latin America and the Caribbean, causing disability and personal, family and economic losses. It is important to prioritize epidemiological surveillance and early diagnosis of this disease in order to reveal its real prevalence and direct resources to preventive actions, diagnosis and early treatment. Lay Summary Chromoblastomycosis is a slowly progressing chronic disease caused by melanized fungi. We collected data from South America and the Caribbean covering 1969-2019, the 132 articles included 2 081 patients, mean disease duration was 10.8 years. Fonsecaea pedrosoi and Cladophialophora carrionii predominated.

show abstract

Chromomycosis, an unusual cause of cicatricial ectropion: a case report

Cited by 3 publications

References 0 publications

Descrição Da Farmacoterapia Da Cromoblastomicose: Revisão Da Literatura

Descrição Da Farmacoterapia Da Cromoblastomicose: Revisão Da Literatura

Molecular epidemiology and clinical‐laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil

Chromoblastomycosis in Latin America and the Caribbean: Epidemiology over the past 50 years

Contact Info

Product

Resources

About